Navigation Links
TGen, Barrow and PCH receive $4 million grant to study genetic basis of brain injuries
Date:12/4/2013

PHOENIX, Ariz. Dec. 4, 2013 In an effort to lower medical costs, identify patients at risk for injury, and speed patient recovery, scientists will attempt to identify a molecular signal that indicates severity of brain-injury during a $4 million, five-year federal grant to Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix Children's Hospital and the Translational Genomics Research Institute (TGen).

The molecular profile comprised of RNA, the body's relay messenger between DNA and protein could help identify which patients are most at risk for vasospasm after hemorrhagic stroke. Hemorrhagic stroke can occur as:

  • Subarachnoid hemorrhage, or the bleeding into the area between the brain and a thin membrane that covers it.
  • Ruptured brain aneurysm, which is an abnormal bulge or ballooning in the wall of an artery within the brain.

By identifying this RNA molecular marker, a new standard of individualized care could be established, enabling medical teams to respond more rapidly to quickly changing health conditions, and allowing earlier intervention to prevent a secondary injury from occurring.

"We hope this study will lead to less injury, less testing and cost, and shorter stays in the hospital," said Dr. Yashar Kalani, M.D. and Ph.D., a resident physician in Neurological Surgery and assistant professor at the Barrow Neurological Institute and one of the study's principal investigators. Additional investigators at Barrow include Drs. Robert Spetzler, Peter Nakaji, Felipe Albuquerque and Cameron McDougall.

Vasospasms are characterized by bleeding in the brain that causes irritation and nearby blood vessels to spasm and narrow. This decreases blood flow to the brain, which can result in damage or even death to parts of the brain.

Only about half of patients with brain-aneurysm ruptures survive, and those who do survive often are severely disabled for life. In the 10 days following such ruptures, blood vessels can narrow, leading to loss of oxygen, strokes and brain damage.

"If we knew what is happening during this period, we might be able to intervene and prevent the secondary injury," Dr. Kalani said.

Barrow will provide patient care and collect blood and spinal fluid samples that will be analyzed by TGen. A recent TGen study showed spinal fluid could be sequenced for RNA biomarkers. Samples will be checked daily to compare and identify changes.

Another part of the study will be conducted at Barrow's partnership with Phoenix Children's Hospital, where researchers will investigate the effects of intraventricular hemorrhage another form of bleeding in the brain in newborn babies. Intraventricular hemorrhage in newborns occurs secondary to diminished blood flow and oxygen delivery to the brain. Intraventricular hemorrhage is associated with the development of hydrocephalus and damage to the brain that can result in cerebral palsy or other types of motor and cognitive delays.

"This study will get us one step closer to learning what is unique in pediatric stroke so we can provide the best quality care and improve the long term outcomes for these children," said Dr. P. David Adelson, one of the principal investigators of the study at Barrow Neurological Institute at Phoenix Children's Hospital.

"In addition, as this study progresses, we want to know how to identify children at risk, and how they differ from adults with similar conditions, this will not only help us to be more accurate at providing current treatments but to develop new ones." said Dr. Jorge Arango, an investigator affiliated with Barrow Neurological Institute at Phoenix Children's Hospital and with the University of Arizona College of Medicine-Phoenix.

In the study of both adults and children, TGen researchers will use state-of-the-art sequencing to analyze RNA transcripts, searching for biomarkers that could identify at-risk patients.

RNAs are cell molecules made from DNA that help create proteins.

"There has been an explosion over the last several years in our understanding of the functional and regulatory mechanisms modulated by RNA" said Dr. Kendall Van Keuren-Jensen, Ph.D., an Assistant Professor in TGen's Neurogenomics Division and also a principal investigator in the study funded by the National Institutes of Health (NIH).

"We are very excited about the potential for extracellular RNAs to provide us with accessible information about the mechanism of disease, and in doing so, provide us with pre-symptomatic markers of disease," said Dr. Matt Huentelman, Ph.D., an Associate Professor in TGen's Neurogenomics Division and also a principal investigator on the project. "In the best-case scenario, these markers can be coupled with an improved clinical management of the disease, too. In a nutshell, that is what we are exploring under this new grant award."

This type of study is now possible because of continuing improvements in optics and computer speed that enables TGen's cutting-edge technology to sequence at ever-faster rates and at ever-lower costs. While it took 13 years and $2.7 billion to spell out the first human genome, such sequencing can now be done in a matter of days and for less than $5,000.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. TGen, Scottsdale Healthcare study shows drug combination extends pancreatic cancer patient survival
2. Barrow researchers identify
3. Barrow scientists discover ways to optimize light sources for vision
4. Clemson professor receives Menzie Environmental Education Award
5. LSU receives $2 million from NIH for biomedical sciences training for underrepresented students
6. Mary Ann Liebert to receive award for stem cell education at World Stem Cell Summit in San Diego
7. BUSM/BMC receives Grand Challenges Explorations grant to develop next generation condom
8. 83 global health innovations receive Grand Challenges Canada funding
9. Geneticists receive funding to improve citrus production and health
10. Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec
11. Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
Breaking Biology News(10 mins):
(Date:5/24/2016)... , ... May 24, 2016 , ... ... newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization ... imaging and image analysis. The re-branding components include a crisp, refreshed logo and ...
(Date:5/23/2016)... 23, 2016 - Leading CRO,s Use of ... - Frontage Implement a Single Platform to Manage End-to-end Operations Across ... the Bioanalytical lab Frontage Laboratories, a full-service contract research ... and China , has selected IDBS, ... addition to serving as the global electronic lab notebook (ELN), the ...
(Date:5/20/2016)... ... 2016 , ... Kablooe Design, a leading provider of product design and development ... of the business. “We have worked hard to build long-term relationships,” says President and ... and honor of serving their product design and development needs through the years.” , ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
Breaking Biology Technology: